Press-release for stocks for JNJ

Prices are updated after-hours

symbols : JNJ crawled time : 21:00

save search

Health eCareers and AAPPR Expand Partnership to Advance Physician and Provider Recruitment and DE&I Efforts
Published: 2024-04-17 (Crawled : 21:00) - j2global.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| 0.0% | O: 0.12% H: 0.0% C: 0.0%
partnership health

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -0.2% | O: -0.04% H: 0.28% C: -0.16%
stelara fda biosimilar approval teva

New Nationwide Study Finds Majority of Hispanic & Latino/a Employees in the U.S. Experience Pressure to Assimilate and Downplay Aspects of their Personality in Order to Succeed at Work
Published: 2024-04-10 (Crawled : 21:00) - prnewswire.com
MS | News | $90.26 0.2% 0.0% 6.7M

Finance

| -2.28% | O: -0.74% H: 0.09% C: -5.32%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -4.55% | O: -0.64% H: 0.0% C: 0.0%
work order nationwide study

Immunome, Novo, AbbVie Boost Portfolios as Part of 2024 M&A Upswing
Published: 2024-03-26 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -6.97% | O: 0.01% H: 0.0% C: 0.0%
abbvie

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2024-03-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.96% | O: -1.58% H: 0.0% C: 0.0%
LEGN | $47.16 -3.42% -3.54% 820K

Health Technology

| -26.14% | O: -0.27% H: 4.91% C: -2.9%
carvykti fda treatment

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| Email alert Add to watchlist
rybrevant fda first lung approved cancer cell treatment therapy

AstraZeneca Loses Court Challenge to Inflation Reduction Act
Published: 2024-03-01 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -10.29% | O: 0.28% H: 0.0% C: 0.0%
astrazeneca

Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -10.13% | O: 0.56% H: 0.12% C: -0.38%
RPRX | News | $27.885 1.0% 0.99% 2.1M

Health Technology

| -9.8% | O: 0.29% H: 0.08% C: -1.17%
pharma conference health care royalty

FDA Decisions: CMC Issues Thwart Venatorx and Melinta’s Urinary Tract Infecti...
Published: 2024-02-23 (Crawled : 21:00) - biospace.com/
PRGO | $29.94 -0.33% 0.0% 970K

Health Technology

| -5.56% | O: 0.22% H: 0.85% C: 0.85%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.77% | O: 0.28% H: 0.0% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M

Health Technology

| -9.32% | O: 0.28% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -3.77% | O: 0.97% H: 0.0% C: 0.0%
fda

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-07 (Crawled : 21:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -5.11% | O: -2.28% H: 0.0% C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -8.39% | O: -0.63% H: 0.0% C: 0.0%
VNDA | News | $4.97 -5.15% -5.43% 3.9M

Health Technology

| 43.96% | O: 0.27% H: 20.82% C: 11.51%
year pharmaceuticals financial results

Interim report for the first half of 2023/24 – Correction
Published: 2024-02-05 (Crawled : 21:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -7.5% | O: -0.49% H: 0.0% C: 0.0%
first report

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments
Published: 2024-02-01 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -8.89% | O: -0.52% H: 0.0% C: 0.0%
medical therapeutics financial

Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
Published: 2024-01-30 (Crawled : 21:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.3% | O: 0.49% H: 0.14% C: -0.94%
RPRX | News | $27.885 1.0% 0.99% 2.1M

Health Technology

| -3.73% | O: 0.07% H: 0.44% C: -1.08%
pharma year royalty financial results

U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Published: 2024-01-19 (Crawled : 21:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| Email alert Add to watchlist
balversa drug genetic approval food bladder cancer treat grants advanced

White River Bancshares Co. Earns $788,000, or $0.79 Per Diluted Share, in Fourth Quarter 2023 and Earns $2.55 Million, or $2.56 Per Diluted Share for the Year; Highlighted by Double Digit Loan and Deposit Growth Year-Over-year
Published: 2024-01-18 (Crawled : 21:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.48% | O: 0.67% H: 0.0% C: 0.0%
SBNY | $3.3 0.0% 490K

Finance

| 157.81% | O: -11.72% H: 15.04% C: 15.04%
growth

Bioventus Names Robert Claypoole as President and Chief Executive Officer
Published: 2023-12-19 (Crawled : 21:00) - globenewswire.com
BVS S | $4.57 -2.77% -2.84% 100K